Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FD-202
- Development stage
- Unknown
- Lead developer
- Medibis
- Modality
- Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral, Sublingual
01
Overview
FD-202 is a full-spectrum medicinal cannabis oil developed by Medibis, an Australian pharmaceutical company specializing in cannabinoid-based therapies. The formulation is characterized by a high concentration of cannabidiol (CBD), typically 200 mg/mL, and a low concentration of delta-9-tetrahydrocannabinol (THC), generally less than 2 mg/mL. As a full-spectrum extract, it contains a variety of minor cannabinoids, terpenes, and flavonoids derived from the *Cannabis sativa* plant, which are thought to contribute to its therapeutic profile via the entourage effect. FD-202 is currently being evaluated in clinical research, notably in an open-label feasibility study conducted by Southern Cross University's National Centre for Naturopathic Medicine (NCNM), to assess its safety and efficacy in managing anxiety and improving quality of life in adults with Autism Spectrum Disorder (ASD).
- Brand names
- Medibis FD202
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))TRPV1 (Transient receptor potential cation channel subfamily V member 1)CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on FD-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FD-202.